Vivos Therapeutics, Inc. (VVOS)
|Net Income (ttm)||-10.71M|
|Trading Day||January 15|
|Day's Range||7.35 - 7.99|
|52-Week Range||5.91 - 9.11|
Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann...
Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock....
HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“ Vivos ”), a medical technology company that offers novel and proprietary alternatives for treating mild-to...
Vivos Therapeutics, Inc., a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed a...
Vivos Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ stock exchange.
Vivos Therapeutics, a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integ... [Read more...]
|IPO Date |
Dec 11, 2020
R. Kirk Huntsman
|Stock Exchange |
|Ticker Symbol |
In 2019, VVOS's revenue was $11.39 million, an increase of 200.43% compared to the previous year's $3.79 million. Losses were -$10.75 million, 27.4% more than in 2018.
According to one analyst, the rating for VVOS stock is "Buy" and the 12-month stock price forecast is 12.00.